トップページ > 教授挨拶 > 教授挨拶(業績)


602.Iihara H, Fujii H, Yoshimi C, Kobayashi R, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A:Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome. Cancer Chemotherapy and Pharmacology DOI: 10.1007/s00280-018-3736-z, 2018
601.Honda M, Kumamaru H, Etoh T, Miyata H, Yamashita Y, Yoshida K, Kodera Y, Kakeji Y, Inomata M, Konno H, Seto Y, Kitano S, Watanabe M, Hiki N:Surgical risk and benefits of laparoscopic surgery for elderly patients with gastric cancer: a multicenter prospective cohort study. Gastric Cancer DOI: 10.1007/s10120-018-0898-7, 2018
600.Nagahashi M, Ling YW, Hayashida T, Kitagawa Y, Futamura M, Yoshida K, Kuwayama T, Nakamura S, Toshikawa C, Yamauchi H, Yamauchi T, Kaneko K, Kanbayashi C, Sato N, Miyoshi Y, Tsuchida J, Nakajima M, Shimada Y, Ichikawa H, Lyle S, Takabe K, Okuda S, Wakai T:Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. JCO Precision Oncology DOI: 10.1200/PO.17.00211, 2018
599.Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Eguchi Nakajima T, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N:A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer DOI: 10.1007/s10120-018-0899-6, 2018
598.Nakamura Y, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, Misawa K, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Bando H, Kawashima Y, Fukunaga T, Gotoh M, Ishibashi T, Shitara K:Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. Ann Surg Oncol DOI: 10.1245/s10434-018-7063-8, 2018
597.Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A:Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology DOI: 10.1007/s00280-018-3711-8, 2018
596.Mori R, Yoshida K, Futamura M, Suetsugu T, Shizu K, Tanahashi T, Tanaka Y, Matsuhashi N, Yamaguchi K:The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells. Gastric Cancer DOI:10.1007/s10120-018-0881-3, 2018
595.Maeda K, Matsuhashi N, Takahashi T, Suetsugu T, Iwata Y, Imai T, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Osada S, Yoshida K:Sarcoidosis as Hepatic, Splenic, and Para-aortic Lymph Nodules, Mimicking Colon Cancer Metastases: A Case Report. Journal of Digestive Diseases and Hepatology 2018(02) DOI: 10.29011/2574-3511, 2018
594.Gaowa S, Futamura M, Tsuneki M, Kamino H, Tajima JY, Mori R, Arakawa H, Yoshida K.:Possible role of p53/Mieap-regulated mitochondrial quality control as a tumor suppressor in human breast cancer. Cancer Science 109(12):3910-3920, 2018
593.Tanaka Y, Ueno T, Yoshida N, Akutsu Y, Takeuchi H, Baba H, Matsubara H, Kitagawa Y, Yoshida K.:The effect of an elemental diet on oral mucositis of esophageal cancer patients treated with DCF chemotherapy: a multi‑center prospective feasibility study (EPOC study). Esophagus 15(4):239-248, 2018
592.Tajirika T, Tokumaru Y, Taniguchi K, Sugito N, Matsuhashi N, Futamura M, Yanagihara K, Akao Y, Yoshida K:DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells. International Journal of Molecular Sciences 19(7):2005, 2018
591.Matsumoto K, Matsuhashi N, Takahashi T, Tanahashi T, Matsui S, Suetsugu T, Tajima JY, Imai T, Imai H, Tanaka Y, Yamaguchi K, Suzui N, Miyazaki T, Yoshida K:Local recurrence of T1a rectal cancer following radical endoscopic mucosal resection: A case report. Molecular and Clinical Oncology 9(3):305-309, 2018
590.Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K.:Recent advancements in esophageal cancer treatment in Japan. Annals of Gastroenterological Surgery 2(4):253-265, 2018
589.Imai T, Abe T, Uemura N, Yoshida K, Shimizu Y.:Immediate extubation after esophagectomy with three‑field lymphadenectomy enables early ambulation in patients with thoracic esophageal cancer. Esophagus 15(3):165-172, 2018
588.Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, Tanabe K, Ohdan H:The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer 21(2):315-323, 2018
587.Matsuhashi N, Takahashi T, Matsui S, Tanahashi T, Imai H, Tanaka Y, Yamaguchi K, Yoshida K.:A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. International Journal of Oncology 52(5):1391-1400, 2018
586.Iwata Y, Ito S, Misawa K, Ito Y, Komori K, Abe T, Shimizu Y, Tajika M, Niwa Y, Yoshida K, Kinoshita T.:Incidence and treatment of metachronous gastric cancer after proximal gastrectomy. Surgery Today 48(5):552-557, 2018
585.Iwata Y, Tanaka C, Komori S, Nagao N, Kawai M, Yoshida K, Kunieda K.:Lobulated esophageal schwannoma resected with concurrent approach from the thorax and cervix. World Journal of Surgical Oncology 16(1):29, 2018
584.Tajima JY, Futamura M, Gaowa S, Mori R, Tanahashi T, Tanaka Y, Matsuhashi N, Takahashi T, Yamaguchi K, Miyazaki T, Yoshida K:Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer. Journal of Cancer 9(2):358-366, 2018
583.Matsuhashi N, Yoshida K, Yamaguchi K, Tanahashi T.:Molecular Diagnosis and Targeted Therapy for Gastric Cancer. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. 63-80, 2018
582.Okuno K, Aoyama T, Oba K, Yokoyama N, Matsuhashi N, Kunieda K, Nishimura Y, Akamatsu H, Kobatake T, Morita S, Yoshikawa T, Sakamoto J, Saji S:Randomized Phase III Trial Comparing surgery alone to UFT+PSK for Stage II Rectal Cancer (JFMC38 trial). Cancer Chemotherapy and Pharmacology 81(1):65-71, 2018
581.Oshima T, Tsuburaya A, Yoshida K, Yoshikawa T, Miyagi Y, Guan J, Tan P, Sakamoto J, Tanaka S:An ancillary biomarker study in the SAMIT randomized trial: Sequential paclitaxel followed by UFT or S-1 versus UFT or S-1 alone as adjuvant chemotherapy for T4a/b gastric cancer. Annals of Cancer Research and Therapy 26(1):39-42, 2018
580.Fujii H, Hirose C, Ishihara M, Iihara H, Imai H, Tanaka Y, Matsuhashi N, Takahashi T, Yamaguchi K, Yoshida K, Suzuki A:Improvement of Dysgeusia by Polaprezinc, a Zinc-L-carnosine, in Outpatients Receiving Cancer Chemotherapy. Anticancer Research 38(11), 6367-6373, 2018
579.Etoh T, Honda M, Kumamaru H, Miyata H, Yoshida K, Kodera Y, Kakeji Y, Inomata M, Konno H, Seto Y, Kitano S, Hiki N.:Morbidity and mortality from a propensity score-matched, prospective cohort study of laparoscopic versus open total gastrectomy for gastric cancer: data from a nationwide web-based database. Surgical Endoscopy 32(6):2766-2773, 2018
578.Das K, Taguri M, Imamura H, Sugimoto N,
Nishikawa K, Yoshida K, Tan P, Tsuburaya A.:Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. Cancer Letters 412(2018):208-215, 2018
577.Taniguchi K, Iwatsuki A, Sugito N, Shinohara H, Kuranaga Y, Oshikawa Y, Tajirika T, Futamura M, Yoshida K, Uchiyama K, Akao Y:Oncogene RNA helicase DDX6 promotes the process of c-Myc expression in gastric cancer cells. Molecular Carcinogenesis 57(5):579-589, 2018
576.Fujitani K, Ando M, Sakamaki K, Terashima M, Kawabata R, Ito Y, Yoshikawa T, Kondo M, Kodera Y, Yoshida K.:Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer. BJS Open 1(6):165-174, 2018
575.Kakeji Y, Takahashi A, Udagawa H, Unno M, Endo I, Kunisaki C, Taketomi A, Tangoku A, Masaki T, Marubashi S, Yoshida K, Gotoh M, Konno H, Miyata H, Seto Y, National Clinical Database:Surgical outcomes in gastroenterological surgery in Japan:Report of National Clinical database 2011-2016. Annals of Gastroenterological Surgery 2(1)37-54, 2018
574.Hiki N, Honda M, Etoh T, Yoshida K, Kodera Y, Kakeji Y, Kumamaru H, Miyata H, Yamashita Y, Inomata M, Konno H, Seto Y, Kitano S.:Higher incidence of pancreatic fistula in laparoscopic gastrectomy.Real-world evidence from a nationwide prospective cohort study. Gastric Cancer 21(1):162-170, 2018
573.Yoshida K, Honda M, Kumamaru H, Kodera Y, Kakeji Y, Hiki N, Etoh T, Miyata H, Yamashita Y, Seto Y, Kitano S, Konno H:Surgical outcomes of laparoscopic distal gastrectomy compared to open distal gastrectomy: A retrospective cohort study based on a nationwide registry database in Japan. Annals of Gastroenterological Surgery 2(1):55-64, 2018
572.松橋延壽、吉田和弘:Conversion surgeryの考え方─Precision medicineからPrecision surgeryへの幕開け. 医学のあゆみ 266(9) 医歯薬出版株式会社, 733-740, 2018
571.田中善宏、吉田和弘、末次智成、今井健晴、山口和也:Ⅷ. 食道癌の治療 (4)食道再建 1)胃を用いた再建. 日本臨牀 増刊号 食道癌(第2版) 76(8):311-319, 2018
570.高橋孝夫、松橋延壽、吉田和弘:主題I:大腸癌に対する化学療法の進歩と最近の話題.VI.進行再発大腸癌に対する新規分子標的薬の開発. 日本大腸肛門病学会雑誌 71(10):417-424,2018
569.松本圭太、松井聡、今井寿、田中善宏、松橋延壽、高橋孝夫、山口和也、齊藤智恵美、宮崎龍彦、吉田和弘:腹腔鏡下肝切除術を施行した甲状腺癌肝転移の1例. 日本外科系連合学会誌 43(4):712-718, 2018
568.棚橋利行、吉田和弘、山口和也:胃癌化学療法の現状と展望. 日本消化器病学会雑誌 115(6):500-506, 2018
567.二村学、吉田和弘:Precision medicine に向けたゲノム解析に基づく胃癌新分類の試み. Bio Clinica 33(437) 66-71, 2018
566.田中善宏、吉田和弘:特集 手術を知って栄養指導に活かそう! 術後栄養障害の原因と対応 食道癌術後の栄養障害―原因と対応 臨床栄養 132(4) 386-392, 2018
565.棚橋利行、山口和也、吉田和弘:高齢者胃癌の化学療法. 日本臨牀 76(3):488-493, 2018
564.富松英人、藤本敬太、久保田全哉、井深貴士、松橋延壽、高橋孝夫、荒木寛司、清水雅仁、吉田和弘、松尾政之:大腸CT検査の長所とピットフォール. Rad Fan 16(8):30-33, 2018
563.吉田和弘、今井健晴、山口和也:7.幽門側胃切除術・D2+郭清(開腹) ビジュアルサージカル 消化器外科手術 上部消化管 -イラストと動画で達人の手技を身につける-.秀潤社 82-95, 2018
562.吉田和弘、今井健晴、山口和也:胃 幽門側胃切除術. 5年でマスター 消化器標準手術消化器外科専門医への道. 改訂第2版. メディカルレビュー社 136-144, 2018
561.吉田和弘、今井健晴、山口和也:胃癌NAC後のD2郭清に必要な局所解剖. 臨床外科 73(11)増刊号:68-73, 2018